thrombin receptor peptide sfllrnp and hydrazine

thrombin receptor peptide sfllrnp has been researched along with hydrazine in 2 studies

Compound Research Comparison

Studies (thrombin receptor peptide sfllrnp)	Trials (thrombin receptor peptide sfllrnp)	Recent Studies (post-2010) (thrombin receptor peptide sfllrnp)	Studies (hydrazine)	Trials (hydrazine)	Recent Studies (post-2010) (hydrazine)
92	10	29	12,034	330	3,193

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Matsushita, T; Miyamoto, M; Ohno, M; Ohtake, A; Yamada, N	1
Babula, B; Barnard, MR; Bussel, JB; Frelinger, AL; Li, Y; Linden, MD; Mathur, K; Michelson, AD; Psaila, B; Tate, C	1

Other Studies

2 other study(ies) available for thrombin receptor peptide sfllrnp and hydrazine

Article	Year
TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood. Thrombosis and haemostasis, 2010, Volume: 104, Issue:4 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cell Communication; Cell Separation; Cells, Cultured; Epinephrine; Epoprostenol; Fatty Acids, Unsaturated; Flow Cytometry; Humans; Hydrazines; Leukocytes; Oxazines; Peptide Fragments; Platelet Activation; Receptors, Epoprostenol; Receptors, Thromboxane A2, Prostaglandin H2; Thrombosis	2010
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood, 2012, Apr-26, Volume: 119, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Flow Cytometry; Humans; Hydrazines; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic	2012

Article

Year

TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood.

Thrombosis and haemostasis, 2010, Volume: 104, Issue:4

Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cell Communication; Cell Separation; Cells, Cultured; Epinephrine; Epoprostenol; Fatty Acids, Unsaturated; Flow Cytometry; Humans; Hydrazines; Leukocytes; Oxazines; Peptide Fragments; Platelet Activation; Receptors, Epoprostenol; Receptors, Thromboxane A2, Prostaglandin H2; Thrombosis

2010

In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.

Blood, 2012, Apr-26, Volume: 119, Issue:17

Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Flow Cytometry; Humans; Hydrazines; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic

2012